AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
zofenopril 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| angiotensin-converting enzyme inhibitors | 2866 | 81872-10-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 30 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 65 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,MAP2K6,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CG,PIM2,PRKDC,STK33,SYK,TEK,TTK,ZAP70 | 40 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,EPHB4,ERBB2,GRK2,MAP2K6,STK33,TEK | 9 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug interaction | 116.88 | 39.78 | 65 | 1351 | 276388 | 90350643 |
| Vascular stent thrombosis | 100.12 | 39.78 | 17 | 1399 | 1099 | 90625932 |
| Bradycardia | 95.16 | 39.78 | 39 | 1377 | 83808 | 90543223 |
| Hyponatraemic syndrome | 67.28 | 39.78 | 11 | 1405 | 563 | 90626468 |
| Syncope | 52.52 | 39.78 | 30 | 1386 | 132633 | 90494398 |
| Herbal interaction | 48.37 | 39.78 | 7 | 1409 | 158 | 90626873 |
| Hallucination, gustatory | 45.42 | 39.78 | 6 | 1410 | 67 | 90626964 |
| Hyperhidrosis | 43.93 | 39.78 | 27 | 1389 | 136278 | 90490753 |
| Psychogenic visual disorder | 43.41 | 39.78 | 5 | 1411 | 15 | 90627016 |
| Muscle contracture | 42.87 | 39.78 | 9 | 1407 | 1812 | 90625219 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug interaction | 112.53 | 38.45 | 74 | 997 | 266925 | 42353339 |
| Enzyme inhibition | 57.95 | 38.45 | 8 | 1063 | 76 | 42620188 |
| Initial insomnia | 45.47 | 38.45 | 12 | 1059 | 4018 | 42616246 |
| Blood glucose fluctuation | 43.93 | 38.45 | 12 | 1059 | 4575 | 42615689 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug interaction | 213.75 | 31.68 | 136 | 2423 | 500047 | 110086693 |
| Bradycardia | 90.94 | 31.68 | 52 | 2507 | 155465 | 110431275 |
| Vascular stent thrombosis | 71.11 | 31.68 | 17 | 2542 | 4144 | 110582596 |
| Hyponatraemic syndrome | 65.78 | 31.68 | 12 | 2547 | 785 | 110585955 |
| Ventricular arrhythmia | 60.51 | 31.68 | 18 | 2541 | 10069 | 110576671 |
| Enzyme inhibition | 53.80 | 31.68 | 8 | 2551 | 145 | 110586595 |
| Hypertensive crisis | 48.46 | 31.68 | 19 | 2540 | 24353 | 110562387 |
| Hallucination, gustatory | 42.98 | 31.68 | 6 | 2553 | 68 | 110586672 |
| Syncope | 40.24 | 31.68 | 35 | 2524 | 202501 | 110384239 |
| Blood glucose fluctuation | 38.73 | 31.68 | 12 | 2547 | 7686 | 110579054 |
| Psychogenic visual disorder | 38.24 | 31.68 | 5 | 2554 | 33 | 110586707 |
| Pulmonary interstitial emphysema syndrome | 36.88 | 31.68 | 7 | 2552 | 568 | 110586172 |
| Hallucination, olfactory | 36.65 | 31.68 | 7 | 2552 | 587 | 110586153 |
| Herbal interaction | 36.29 | 31.68 | 7 | 2552 | 619 | 110586121 |
| Muscle contracture | 35.46 | 31.68 | 9 | 2550 | 2799 | 110583941 |
| Initial insomnia | 35.19 | 31.68 | 12 | 2547 | 10377 | 110576363 |
| Apraxia | 33.39 | 31.68 | 9 | 2550 | 3531 | 110583209 |
| Inferior vena cava dilatation | 33.25 | 31.68 | 7 | 2552 | 960 | 110585780 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C09AA15 | CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, PLAIN ACE inhibitors, plain |
| ATC | C09BA15 | CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, COMBINATIONS ACE inhibitors and diuretics |
| ATC | C09BB14 | CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, COMBINATIONS ACE inhibitors and calcium channel blockers |
| ATC | C09BX07 | CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, COMBINATIONS ACE inhibitors, other combinations |
| MeSH PA | D000806 | Angiotensin-Converting Enzyme Inhibitors |
| MeSH PA | D000959 | Antihypertensive Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D011480 | Protease Inhibitors |
| CHEBI has role | CHEBI:35457 | EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35620 | vasodilator agent |
| CHEBI has role | CHEBI:35623 | anticonvulsant |
| CHEBI has role | CHEBI:50266 | prodrug |
| CHEBI has role | CHEBI:68494 | apoptosis inhibitor |
| CHEBI has role | CHEBI:77307 | cardioprotective agent |
| CHEBI has role | CHEBI:49103 | drug metabolite |
Related Drugs by ATC class:
C09AA ACE inhibitors, plain 15 drugs
C09BA ACE inhibitors and diuretics 11 drugs
C09BB ACE inhibitors and calcium channel blockers 13 drugs
C09BX ACE inhibitors, other combinations 7 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hypertensive disorder | indication | 38341003 | DOID:10763 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.94 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Angiotensin-converting enzyme | Enzyme | INHIBITOR | IC50 | 9.40 | CHEMBL | SCIENTIFIC LITERATURE | |||
| Angiotensin-converting enzyme | Enzyme | Ki | 9.40 | CHEMBL | |||||
| Angiotensin-converting enzyme | Enzyme | IC50 | 8.10 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D03767 | KEGG_DRUG |
| C0078836 | UMLSCUI |
| CHEBI:78539 | CHEBI |
| ZED | PDB_CHEM_ID |
| CHEMBL331378 | ChEMBL_ID |
| CHEMBL2105776 | ChEMBL_ID |
| DB13166 | DRUGBANK_ID |
| C044958 | MESH_SUPPLEMENTAL_RECORD_UI |
| 92400 | PUBCHEM_CID |
| 6462 | IUPHAR_LIGAND_ID |
| 5535 | INN_ID |
| 81938-43-4 | SECONDARY_CAS_RN |
| 290ZY759PI | UNII |
| DB08766 | DRUGBANK_ID |
| 259493 | RXNORM |
| 008183 | NDDF |
| 008184 | NDDF |
| 703340007 | SNOMEDCT_US |
| 703341006 | SNOMEDCT_US |
| 703342004 | SNOMEDCT_US |
| 703662000 | SNOMEDCT_US |
| 703663005 | SNOMEDCT_US |
| C0085065 | UMLSCUI |
| CHEMBL16332 | ChEMBL_ID |
| 75176-37-3 | SECONDARY_CAS_RN |
| 3034048 | PUBCHEM_CID |
| 6463 | IUPHAR_LIGAND_ID |
| 6599 | INN_ID |
| 4G4WDK2YBS | UNII |
| CHEBI:82602 | CHEBI |
| 290ZY759PI | INXIGHT DRUGS |
| 4G4WDK2YBS | INXIGHT DRUGS |
Pharmaceutical products:
None